Picture of Phathom Pharmaceuticals logo

PHAT — Phathom Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Phathom Pharmaceuticals Inc expected to post a loss of $1.31 a share - Earnings Preview

* Phathom Pharmaceuticals Inc  PHAT.OQ   PHAT.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 9 for the period ending March 31 2024
    * The Florham Park New Jersey-based  company is expected to
report
revenue of $2.047 million, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Phathom Pharmaceuticals
Inc is
for a loss of $1.31 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Phathom
Pharmaceuticals Inc is $25.00​, above​ its last closing price
of $10.84. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.10       -1.08      -1.39     Missed  -29.1
 Sep. 30 0001  -0.87       -0.89      -0.76     Beat    14.7
 Jun. 30 2023  -0.94       -0.98      -0.84     Beat    14.2​
 Mar. 31 2023  -1.23       -1.26      -0.89     Beat    29.4
 ​​Dec.        -1.34       -1.35      -1.33     Beat    1.6
 31 2022                                                
 Sep. 30 2022  -1.32       -1.32      -1.32     Met     -0.2​
 Jun. 30 2022  -0.99       -1.03      -1.33     Missed  -29.1
 Mar. 31 2022  -0.98       -0.97      -1.07     Missed  -10.5
 This summary was machine generated May 7 at 14:43 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Phathom Pharmaceuticals

See all news